Citadel Advisors’s Columbia Research Enhanced Value ETF REVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-11,016
Closed -$312K – 14028
2025
Q4
$312K Buy
11,016
+41
+0.4% +$1.16K ﹤0.01% 10057
2025
Q3
$307K Sell
10,975
-8,816
-45% -$240K ﹤0.01% 10319
2025
Q2
$520K Buy
+19,791
New +$491K ﹤0.01% 8537
2025
Q1
– Sell
-13,556
Closed -$335K – 15398
2024
Q4
$335K Buy
+13,556
New +$350K ﹤0.01% 9428
2024
Q3
– Sell
-17,206
Closed -$401K – 15072
2024
Q2
$401K Buy
+17,206
New +$400K ﹤0.01% 8513
2023
Q4
– Sell
-13,432
Closed -$274K – 15088
2023
Q3
$274K Buy
+13,432
New +$283K ﹤0.01% 9331
2022
Q4
– Sell
-14,500
Closed -$260K – 15357
2022
Q3
$260K Buy
+14,500
New +$284K ﹤0.01% 9882

Other funds holding REVS

Citadel Advisors's REVS Position: Q1 2026 in Review

Citadel Advisors sold out of Columbia Research Enhanced Value ETF (REVS) in Q1 2026, closing a stake of 11,016 shares — an estimated $312K sold.

Citadel Advisors first reported a position in REVS in Q3 2022 and held it in 7 quarters. The position peaked at $520K in Q2 2025. 37 funds tracked by Wall St. Rank hold REVS as of Q1 2026.

  • Citadel Advisors reported no remaining Columbia Research Enhanced Value ETF position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 11,016 Columbia Research Enhanced Value ETF shares in Q1 2026, an estimated $312K.
  • Citadel Advisors first reported a position in Columbia Research Enhanced Value ETF in Q3 2022 and held it in 7 quarters.
  • Citadel Advisors's Columbia Research Enhanced Value ETF position peaked at $520K in Q2 2025.
  • 37 funds tracked by Wall St. Rank held Columbia Research Enhanced Value ETF as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.